Published On: 2/20/2020
TARGET-IBD Poster & Oral Presentation at ECCO
Earlier this month, TARGET attended the 15th annual Congress of European Crohn’s and Colitis Organisation (ECCO) event in Vienna, Austria. TARGET was selected to present two encores from the 2019 American College of Gastroenterology meeting.
The first was accepted as a poster, “Oral Mesalamine Use in Crohn’s Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study”. It was presented by Bruce Sands, MD, a TARGET-IBD steering committee Co-Chair and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai.
The second was accepted as a digital oral presentation titled “Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort”. It was also presented by Dr. Sands.
The focus of the talk was on characterizing inflammatory bowel disease-related medications in elderly patients. Notable findings were that mesalamine use was the most common medication among patients over 65 years of age (even for Crohn’s disease patients), and that use of anti-tumor necrosis factor alpha medications decreased in patients in the older age groups when compared to patients under 30 years of age. The presentation was additionally honored as the Best Digital Oral Presentation of Session 3.
You can find all of the presented TARGET-IBD posters on our Publications page.
About TARGET PharmaSolutions
Headquartered in Durham, NC, TARGET PharmaSolutions is a privately held real-world data solutions company that provides pharmaceutical and biotechnology partners a more efficient way to generate data in the real-world setting. TARGET PharmaSolutions has six disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), TARGET-IBD (inflammatory bowel disease), TARGET-DERM (immune mediated skin conditions) and TARGET-HBV (hepatitis B).
For more information, visit www.targetpharmasolutions.com.
984.234.0268 ext 205
05/07/2020Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
04/14/2020TARGET-NASH Observational Study Reaches 5,000 Enrolled Patients
03/17/2020TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry Partnerships
03/13/2020TARGET PharmaSolutions Launches Real-World Asthma Study